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Abstract
Introduction: With the trend of increasing incidence of autoimmune diseases, laboratories are faced with exponential growth of the requests for 
tests relating the diagnosis of these diseases. Unfortunately, the lack of laboratory personnel experienced in this specific discipline of laboratory 
diagnostic, as well as an unawareness of a method limitation often results in confusion for clinicians. The aim was to gain insight into number and 
type of Croatian laboratories that perform humoral diagnostics with the final goal to improve and harmonize laboratory diagnostics of autoimmune 
diseases in Croatia.
Materials and methods: In order to get insight into current laboratory practice two questionnaires, consisting of 42 questions in total, were crea-
ted. Surveys were conducted using SurveyMonkey application and were sent to 88 medical biochemistry laboratories in Croatia for the first survey. 
Out of 33 laboratories that declared to perform diagnostic from the scope, 19 were selected for the second survey based on the tests they pleaded to 
perform. The survey comprised questions regarding autoantibody hallmarks of systemic autoimmune diseases while regarding organ-specific auto-
immune diseases was limited to diseases of liver, gastrointestinal and nervous system.
Results: Response rate was high with 80 / 88 (91%) laboratories which answered the first questionnaire, and 19 / 19 (1.0) for the second questi-
onnaire. Obtained results of surveys indicate high heterogeneity in the performance of autoantibody testing among laboratories in Croatia.
Conclusions: Results indicate the need of creating recommendations and algorithms in order to harmonize the approach to laboratory diagnostics 
of autoimmune diseases in Croatia.
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Laboratory medicine of autoimmune diseases is a 
growing discipline of laboratory medicine in gen-
eral, and many laboratories expand their panel of 
tests with new methodologies for autoantibody 
detection. Methods in laboratory medicine of au-
toimmune diseases differ in many aspects like the 
antigen profiles, sensitivity and specificity (1). Limi-
tations like the lack of standardized reference sam-
ples of defined specificities and different sources 
of antigens (recombinant vs. native) are the main 
source of results discrepancy between different 
methods. Very heterogeneous manner of result re-
porting is the consequence of both lack of nomen-
clature uniformity and consensus regarding result 
interpretation. Finally, the lack of experience and 
education of laboratory personnel in the diagnos-
tics of certain autoimmune diseases, as well as an 
unawareness of a method limitation often results 
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in confusion for clinicians. Therefore, standardiza-
tion and harmonization in this field of laboratory 
diagnostic is essential (2). Efforts were made to 
provide the recommendations for humoral auto-
immune diagnostics that recently resulted with In-
ternational recommendations for the assessment 
of anti-nuclear antibody testing published by the 
European Autoimmunity Standardization Initiative 
(EASI) (3). For most systemic and organ-specific au-
toimmune diseases diagnostic criteria or classifica-
tion criteria have been introduced (4-12). Autoanti-
bodies included in those criteria are an important 
tool for diagnosis of autoimmune diseases. This 
prompted the initiative from Croatian Society of 
Medical Biochemistry and Laboratory Medicine 
(CSMBLM) to form a Working group (WG) for labo-
ratory diagnostics of autoimmune diseases with 
following goals: to screen the current practice in 
performing laboratory medicine of autoimmune 
diseases in Croatia, to identify the main problems 
and accordingly propose the recommendations 
that would improve and harmonize laboratory 
medicine of autoimmune diseases. The aim of the 
study was to gather information about the meth-
odology, interpretation and algorithms used in 
laboratory medicine of autoimmune diseases in 
Croatia. WG designed two-step questionnaires in 
order to obtain that information. This study sum-
marises the outcome of these questionnaires and 
provides the insight into the main problems and 
sources of heterogeneity in performance of au-
toantibody testing. 
Materials and methods
In order to obtain information about the current 
practice in laboratory diagnostics of autoimmune 
diseases in Croatia two surveys were conducted 
using SurveyMonkey application (SurveyMonkey 
Inc., Palo Alto, California, USA). The first survey was 
a questionnaire that contained 17 questions with 
predefined answers that aimed to identify labora-
tories which perform diagnostics of autoimmune 
diseases and to obtain general information like 
laboratory organization, number of tests per 
month, turnaround time (TAT), etc. The contacts of 
laboratory managers of all medical biochemistry 
laboratories in Croatia were obtained from Croa-
tian Chamber of Medical Biochemists. The survey 
was sent to all laboratories within secondary 
healthcare facilities (general and county hospitals), 
tertiary healthcare facilities (university hospital/
university hospital centre), private laboratories 
and specialized health institutions (total number 
of 88 laboratories). The survey was sent to the e-
mail addresses of the laboratory managers with a 
suggestion that a laboratory professional respon-
sible for laboratory diagnostics of autoimmune 
diseases should complete the survey. In case that 
laboratory does not perform any of the tests listed 
in question two of the first survey, survey partici-
pants were instructed to skip all following ques-
tions and to conclude the survey. The link for the 
survey was distributed via e-mails on September 
26th 2014 and was closed on April 22nd 2015. The 
laboratories within primary healthcare facilities 
were excluded from the survey considering that 
they do not perform the tests for laboratory diag-
nostics of autoimmune diseases. After the collec-
tion of the responses, from 33 laboratories that de-
clared to perform diagnostic from the scope, 19 
were selected for the second survey based on the 
tests they pleaded to perform. This survey was cre-
ated in the same application and contained 25 
questions in order to obtain more detailed infor-
mation regarding detection of selected tests. The 
link for the second survey was also sent via e-mails 
on October 22nd 2015 and was closed on Novem-
ber 28th 2015.
For more transparent review, questions and of-
fered answers from both questionnaires are pre-
sented together in Table 1.
In total, both questionnaires included 42 questions 
that could roughly be divided in 6 categories: lab-
oratory organisation, definition of the tests from 
the scope and organisation of routine work (N = 8), 
antinuclear antibodies (ANA), antibodies to double 
stranded DNA (anti-dsDNA) and antibodies to ex-
tractible nuclear antigens (anti-ENA) testing (N = 
20), anti-neutrophil cytoplasmic antibodies (ANCA) 
testing (N = 6), antiphospholipid (aPL) antibodies 
testing (N = 3), celiac disease (N = 3), autoimmune 
liver diseases testing (N = 2). 
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Table 1. Questions, offered and collected answers in CSMBLM WG survey
Question Answers Received answers, N (%)
First survey (N = 80)
1. Please enter the data of your 
institution.
Descriptive answer 80 (100)
2. Please specify humoral 
immunodiagnostic analyses that are 
performed in your laboratory?
Systemic autoimmune rheumatic diseases (ANA, ENA, anti-dsDNA, 
anti-histones, anti-nucleosomes, CENP, anti-CCP, RF) 30 (38)
Systemic vasculitis and glomerulonephritis (ANCA, anti-GBM, 
anti-PR3, anti-MPO)
14 (18)
Autoimmune liver diseases (AMA, AGLM, LKM, LC-1, SLA, ASGPR) 6 (8)
Antiphospholipid syndrome (aCL, β2GPI, LA, aPS, anti-PT/PS) 12 (15)
Autoimmune bowel diseases (ASCA, APS, EMA, anti-tTG, AGA, 
anti-DGP)
11 (14)
Autoimmune neurological disorder / paraneoplastic syndrome ( 
anti-Hu, anti-Yo, anti-Ri)
2 (3)
None of the analysis stated above. 47 (59)
Question Answers Received answers, N (proportion)
First survey for participating laboratories performing humoral immunodiagnostic analyses (N = 33)*
3. What is the type of institution were 
your laboratory operates?
General/county hospital 11 (0.33)
Specialized health institution 6 (0.19)
University hospital/University hospital centre 9 (0.27)
Private institution 7 (0.21)
Other (specify) 0 (0)
4. What is the dynamics of providing 
laboratory reports?
24 hours 14 (0.42)
Up to 7 days 4 (0.13)
7 - 30 days 14 (0.42)
> 30 days 1 (0.03)
5. What is the total number of 
humoral immunodiagnostic tests per 
month in your laboratory?
< 500 24 (0.73)
500-1000 4 (0.12)
> 1000 5 (0.15)
6. Please state the methods and units 
next to the tests (from the list) that 
you perform.
Descriptive answer for ANA, ENA, anti-dsDNA, anti-histones, 
anti-nucleosomes, CENP, anti-CCP, RF, ANCA, anti-GBM, anti-PR3, 
anti-MPO, AMA, SMA, LKM, LC-1, SLA, ASGPR, aCL, anti-B2GPI, LA, 
APS, anti-PT/PS, ASCA, APC, EMA, anti-tTG, AGA, anti-DGP, anti-Hu, 
anti-Yo, anti-Ri.
33 (1.0) 
(see text and Tables 
3 - 7)
7. If you use IIF for ANA determination, 
what is your initial dilution? Descriptive answer
7 (0.21) 
(details in Table 3)
8. If you determine ANA with 




Depending on the fluorescence type 0 (0)
9. If you determine ANA using IIF, do 
you describe the type of fluorescence?
Yes 7 (0.21)
No 0 (0)
10. If ANA screening is positive, do 
you automatically determine specific 
autoantibodies?
Yes, depending on the fluorescence pattern 2 (0.06)
Yes, depending on the ANA titre 4 (0.12)
If requested, independently of ANA-screen test result 2 (0.06)
No 6 (0.18)
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11. If you use some other methods 
instead of IIF for ANA screen, do you 
specify the antigens included in the 




12. Do you determine the titre of 
autoantibodies for analysis (besides 
ANA) that are tested with IIF? If yes, 
please state which tests?
Yes 6 (0.18) (details in text)
No 2 (0.06)
13. If you perform ANCA screening 
test by IIF method, do you describe 
the type of fluorescence? If yes, please 
state which type of fluorescence you 
describe.
Yes 3 (0.09) (details in text)
No 0 (0)
14. If you determine anti-PR3 and 
anti-MPO with ANCA-screening, 
please choose the option that 
corresponds with your protocol.
They are determined in all samples regardless of the results of 
ANCA-screening test
0 (0)
They are determined within ANCA-screening test 0 (0)
They are only determined in samples that are positive in 
ANCA-screening test.
4 (0.12)
15. Do you determine the 
concentration of total IgA in serum/
plasma prior to determination of EMA 




16. Do you participate in external 
quality assessment (EQA) with analysis 
stated in Question No. 6. If the answer 
is “partially”, please specify the 
analysis that are included in EQA.
Yes 13 (0.39)
No 12 (0.36)
Partially (specify) 5 (0.15) (details in text)
17. Please state the dynamics of 
participation in EQA schemes.
Monthly 2 (0.06)
Every 2 - 4 months 5 (0.15)
Every 6 months 9 (0.27)
Once a year 2 (0.06)
Second survey (N = 19)
Questions Answers Received answers, N (proportion)
1. When determining ANA-screen 
with IIF method, which types of 
fluorescence do you recognize 
and report? (Possibility of multiple 
answers).
Homogenous 7 (0.37)
Speckled / granular 7 (0.37)
Centromeres 7 (0.37)
Nucleolar 7 (0.37)
Nuclear envelope 5 (0.26)
Mitotic apparatus 4 (0.21)
Fluorescence of cytoplasm 6 (0.32)
Other (specify) 4 (0.21) 
(details in Table 3)
We do not perform ANA test with IIF 12 (0.63)
2. When determining ANA-screen 
with IIF do you report different types 
of fluorescence in the same sample?
We report different types of fluorescence and the corresponding 
titres
2 (0.11)
We report different types of fluorescence but only one titre 4 (0.21)
We do not report different types of fluorescence 0 (0)
Other (please describe) 1 (0.05) 
(details in Table 3)
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3. When determining ANA-screen 
with IIF, slides are examined by:
One examiner 1 (0.05)
Two examiners (results are reported in agreement) 3 (0.16)
One examiner in consultation with another if needed. 3 (0.16)
Other (please describe) 0 (0)
4. What is the highest dilution when 
you determine ANA titre in IIF ANA 
screening?
Maximally up to: (please state a dilution) 5 (0.26) 
(details in Table 3)
We dilute till no detectable fluorescence 2 (0.11)
5. In which cases after ANA-screen test 
do you determine anti-dsDNA?
We do not determine anti-dsDNA 1 (0.05)
Only when ordered, regardless of the ANA result 6 (0.32)
Only when ordered and ANA-screen result is positive 1 (0.05)
Only when ordered and ANA IIF screen result is positive with a 
specific type of fluorescence
0 (0)
Always with positive ANA result, even if anti-dsDNA was not 
ordered.
4 (0.21)
Only when ordered and ANA IIF screen result is positive with a 
titre higher then (please insert titre)
1 (0.05)
(details in Table 5)




7. Which autoantibodies are 
included in your ENA-screening test? 
(Possibility of multiple answers.)
anti-SS-A (Ro60) 4 (0.21)
anti-Ro52 (TRIM21) 1 (0.05)
anti-SS-B 4 (0.21)
anti-ribosome P protein 1 (0.05)
anti-U1RNP 4 (0.21)
anti-Sm 4 (0.21)
anti-Scl-70 (Topoisomerase-1) 4 (0.21)
anti-Jo-1 4 (0.21)
anti-CENP 1 (0.05)
other (please specify) 1 (0.05) 
(details in Table 4)
8. What method do you use for 
ENA-screening test?
ELISA 3 (0.16)
Immunoblot (Line blot) 0 (0)
Multiplex (Luminex) 0 (0)
FEIA 1 (0.05)
Other (please specify) 0 (0)
9. Results of ENA-screening are 
expressed as:
Semiquantitative (ratio) 1 (0.05)
Qualitative (positive/negative) 3 (0.16)
10. Which specific ENA antibodies do 
you determine? (Possibility of multiple 
answers.)
We do not determine ENA specific antibodies 7 (0.37)
anti-SS-A (Ro60) 12 (0.63)
anti-Ro52 (TRIM21) 5 (0.26)
anti-SS-B (La) 12 (0.63)
anti-ribosome P protein 4 (0.21)
anti-U1RNP 11 (0.58)
anti-Sm 11 (0.58)
anti-Scl-70 (Topoisomerase-1) 12 (0.63)
anti-Jo-1 11 (0.58)
anti-CENP 10 (0.53)
other (please specify) 6 (0.32)
(details in Table 4)
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11. Which method do you use for ENA 
specific antibodies determination?
ELISA 3 (0.16)
Immunoblot (Line blot) 1 (0.05)
Multiplex (Luminex) 3 (0.16)
FEIA 4 (0.21)
Other (please specify) 1 (0.05)
(details in Table 4)
12. Do you use algorithm for anti-ENA 
determination?
No, we determine everything that has been ordered 6 (0.32)
Yes, anti-ENA is analysed depending on the ANA-screening result 4 (0.21)
13. Do you have a rule regarding the 
frequency of ENA-specificity repeat 
testing? If yes, please state the rule.
No 18 (0.95)
Yes (state the rule) 1 (0.05) 
(details in text)
14. When only anti-dsDNA and/or 
anti-ENA have been ordered, you 
perform:
ANA-screen test first, and anti-dsDNA/anti-ENA only in the case of 
positive ANA
3 (0.16)
Anti-dsDNA and/or anti-ENA are determined without 
ANA-screening
9 (0.47)
15. Do you include interpretative 
comments on the laboratory report?
No 14 (0.74)
Yes, in the case that fluorescence pattern on ANA-screen test 
indicates unusual antibodies (e.g. antibodies to Golgi complex, 
lysosomes, peroxisomes)
2 (0.11)
Yes, in the case that fluorescence pattern on ANA-screen test 
indicates other antibodies (e.g. AMA, SMA)
3 (0.16)
Other (please specify) 1 (0.05) 
(details in Table 3)
16. As a part of celiac disease 
screening you determine IgG class 
antibodies to:
tissue transglutaminase 2 (0.11)
deamidated gliadin 3 (0.16)
native gliadin 0 (0)
endomysium (EMA) 0 (0)
we do not determine IgG class antibodies in celiac disease 
screening
6 (0.32)
we do not perform celiac disease screening 8 (0.42)
17. When do you determine IgG class 
antibodies in celiac disease screening?
Only when there is a complete IgA deficiency 0 (0)
When there is a complete IgA deficiency and in children ≤ 2 years 3 (0.16)
In case of decreased IgA or in a complete IgA deficiency 0 (0)
In case of decreased IgA or in a complete IgA deficiency and in 
children ≤ 2 years
0 (0)
Always, together with IgA class antibodies 2 (0.11)
18. What is your starting dilution in 
ANCA IIF- screening test?
1 : 5 0 (0)
1 : 10 2 (0.11)
1 : 20 1 (0.05)
1 : 40 0 (0)
We do not perform ANCA-screening test 15 (0.79)
19. In ANCA IIF-screening test, do you 
use formalin-fixed granulocytes?
No 1 (0.05)
Yes, always with ethanol-fixed granulocytes 2 (0.11)
Yes, only in case of ANCA positive test on ethanol-fixed granulocytes 0 (0)
Yes, only in case of pANCA positive test on ethanol-fixed 
granulocytes
0 (0)
Yes, only in case of atypical pANCA positive test on ethanol-fixed 
granulocytes
0 (0)
Yes, only if ANCA is ordered from gastroenterologist 0 (0)
Yes, only in case of positive ANA 0 (0)
Biochemia Medica 2016;26(3):376–94  http://dx.doi.org/10.11613/BM.2016.041 
382
Tešija Kuna A. et al. Autoimmune diagnostics in Croatia
20. Do you determine other ANCA 
specificities except PR3 and MPO 
(elastase, lactoferrin, etc.)? If yes, 
please specify.
Yes (specify) 0 (0)
No 19 (1.0)
21. In the case of positive liver kidney 
microsome (LKM) antibodies with 




We do not determine anti-LKM with IIF method 16 (0.84)
22. In the case of positive AMA with 




We do not determine AMA with IIF method 15 (0.79)
23. Do you use algorithm when 
antiphospholipid antibodies are 
ordered?
No, only aCL antibodies are determined 2 (0.11)
No, only LA is determined 3 (0.16)
No, LA and aCL are determined simultaneously 0 (0)
No, aCL and anti-B2GPI are determined simultaneously 3 (0.16)**
No, aCL, anti-B2GPI and LA are determined simultaneously 3 (0.16)
Yes, anti-B2GPI antibodies are determined depending on the aCL 
results
0 (0)
We do not determine antiphospholipid antibodies 7 (0.37)
24. Which isotypes of aCL do you 
determine?
IgG and IgM 8 (0.42)
IgG, IgM and IgA 0 (0)
We do not determine aCL 11 (0.58)
25. Which isotypes of anti-B2GPI do 
you determine?
IgG and IgM 7 (0.37)
IgG, IgM and IgA 0 (0)
We do not determine anti-B2GPI 12 (0.63)
Question and answers obtained after personal communication with managers of 7 laboratories that perform IIF method 
for antibodies detection
1. Who is authorised to perform 
examination of IIF slides in your 
laboratory?
specialist in medical biochemistry 4 (0.57)
master of medical biochemistry and laboratory medicine 2 (0.29)
other (specify) 1 (0.14)
(details in Table 3)
*Out of 80 participating laboratories, 47 declared to not perform humoral immunodiagnostic analyses (see question 2). 
**Including laboratory that simultaneously determines aCL, anti-B2GPI and aPS.
ANA = antinuclear antibodies. ENA = extractible nuclear antibodies. anti dsDNA = anti-double stranded DNA. SS-A/Ro60 = Anti-
Sjögren’s-syndrome-related antigen A. Ro52 (TRIM21) = Tripartite motif-containing protein 21. SS-B/La = Sjögren syndrome type B 
antigen. U1-RNP = U1 ribonucleoprotein. PM/Scl = Polymyositis/Scleroderma. PCNA = Pleomorphic cell nuclear antigen. Sm = Smith 
antigen. Scl-70 = topoisomerase I. Jo-1 = histidyl tRNA synthetase. CENP = antibodies targeting centromere proteins. anti-CCP = 
antibodies targeting synthetic cyclic citrullinated peptides. RF = rheumatoid factor. ANCA = anti-neutrophil cytoplasmic antibodies. 
anti-PR3 = anti-proteinase 3 antibodies. anti-MPO = anti-myeloperoxidase antibodies. anti-GBM = anti-glomerular basement 
membrane antibodies. AMA = antimitochondrial antibodies. AGLM = Anti-smooth muscle antibody. LKM = liver-kidney microsomal 
antibodies. LC-1 = liver cytosol. SLA = soluble liver antigen. ASGPR= asialoglycoprotein receptor. aCL = anticardiolipin antibodies. 
anti-B2GPI = anti-beta2 glycoprotein I antibodies. LA = lupus anticoagulant. aPS = antiphosphatidilserine antibodies. anti-PT/PS= 
anti-phosphatidylserine/prothrombin antibodies. ASCA = anti-saccharomyces cerevisiae antibodies. APCA = antibodies against 
parietal cells. EMA = anti-endomysium antibodies. anti-tTG = antibodies against tissue transglutaminase. AGA = antibodies against 
native gliadin. anti-DGP = antibodies targeting deamidated gliadin peptides.
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Statistical analysis
Data were collected in the SurveyMonkey applica-
tion, but due to the small number of laboratories 
which perform this scope of diagnostics, no statis-
tical analysis could be applied but the data are 
rather presented as counts and ratios. 
Results
Response on the survey and general 
information of participated laboratories
This survey had a remarkably good response with 
a response rate of 91% (80 / 88 laboratories) for the 
first Survey and 1.0 (19 / 19 laboratories) for the 
second survey. Table 1 summarizes all specific 
questions and offered answers from both surveys 
as well as corresponding counts and ratios from 
received answers with the exception of descriptive 
answers that are presented in following text or ta-
bles.
Out of 80 laboratories, 33 indicated to perform at 
least one of the autoimmune diagnostic tests of-
fered in the questionnaire. This means that around 
40% of all laboratories within the secondary and 
tertiary healthcare facilities as well as specialized 
and private health institutions perform laboratory 
diagnostic of autoimmune diseases. 
General information on aforementioned 33 labo-
ratories including type of laboratory, TAT for tests 
from the scope, participation in EQA scheme with 
frequency are available in Table 1 (questions 3, 4 
and 17 from the first survey). All nine university 
hospital/university hospital Centres and half (11 / 
20) of general/county hospitals in Croatia perform 
this laboratory diagnostic. Number of tests per 
month is available in Table 1 and distribution of 
the type of laboratory relative to the number of 
tests per month is presented in Table 2. Regarding 
the TAT for autoantibody testing, 14 / 33 laborato-
ries declared 24-hour TAT, which mostly refers to 
rheumatoid factor (RF) and/or antibodies target-
ing synthetic cyclic citrullinated peptides (anti-
CCP) (12 / 14 laboratories), while the remaining two 
are private laboratories performing wider spec-
trum of tests. This information was obtained with 
examination of individual responses to question 4 
in the first survey (Table 1). According to informa-
tion available on the web page of Croatian accred-
itation agency, 6 of 33 laboratories are accredited 
according to Croatian normative document: Medi-
cal laboratories - Requirements for quality and 
competence (ISO 15189:2012; EN ISO 15189:2012) in 
the field of humoral laboratory diagnostic of auto-
immune diseases. 
Current practice in immunodiagnostic of 
systemic autoimmune rheumatic diseases
Out of 33 laboratories, 30 have indicated to per-
form tests from the scope of serologic diagnostic 
of systemic autoimmune rheumatic diseases (Ta-
ble 1). 
Assessment of RF and anti-CCP
Tests for serologic diagnostic of rheumatoid arthri-
tis: RF and anti-CCP are performed in 23 of previ-
ously mentioned 30 laboratories; 19 perform both 
tests while 4 laboratories perform only RF and 4 
only anti-CCP. Immunoturbidimetry (N = 16) is the 
most frequent method for RF determination, im-
munonephelometry is used by 4, and enzyme-
linked immunosorbent assay (ELISA), fluorescence 
enzyme immunoassay (FEIA) and latex agglutina-
tion in one laboratory each. The most frequent 
method for anti-CCP determination is electro-
chemiluminescence immunoassay (ECLIA) which is 
performed in 10 laboratories, followed by chemi-
luminescent microparticle immunoassay (CMIA) in 
5, FEIA in 4, ELISA in 3 and microparticle enzyme 
immunoassay (MEIA) in 1 laboratory.
Assessment of ANA, anti-ENA and anti-dsDNA 
antibodies
Determination of ANA is performed in 17 of 30 lab-
oratories. Seven of them are laboratories within 
tertiary healthcare facilities, 5 within secondary 
health care facilities, 3 specialized institution and 2 
are private laboratories. Indirect immunofluores-
cence assay (IIF) on Hep-2 cells (Human epithelial 
type 2 cells) as the reference method for ANA de-
tection is used in 7 / 17 laboratories among which 
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Category Total N N (proportion)




Private laboratory 7 (0.29)
Specialized institution 5 (0.21)
University hospital / University hospital centre 3 (0.12)




University hospital/ University hospital centre 2 (0.50)
> 1000 5 (0.15)
University hospital/University hospital centre
5
4 (0.8)
Specialized institution 1 (0.2)
Table 2. Distribution of the number of tests per month in relation to type of laboratory 
Table 3. Current practice in assessment of ANA testing





IIF on Hep-2 cells 7 (0.41)
FEIA 6 (0.35)
ELISA 3 (0.18)
Line - blot 1 (0.06)
Assessment of ANA by IIF on Hep-2 cells (N = 7) N 
(proportion)





Nuclear envelope 5 (0.71)
Mitotic apparatus 4 (0.57)
Fluorescence of cytoplasm 6 (0.86)
Nuclear dots 4 (0.57)
PCNA– like pattern 3 (0.43)
6 are within tertiary and 1 within secondary health 
care facility. Other methods in use and current 
practice in assessment of ANA are presented in Ta-
ble 3. 
ENA-screen test is performed in four laboratories 
while ENA-specific tests are performed in 12 labo-
ratories. Although classic “ENA” term refers only to 
SS-A/Ro60, SS-B/La, U1-RNP, Sm, Scl-70 and Jo-1 
antigens, it is generally accepted to use the term 
ENA–specific tests for individual specificities in-
stead of the more proper one, ANA–specific tests. 
Data regarding current practice in assessment of 
ENA testing in Croatia is presented in Table 4. 
About half of laboratories performing ANA testing 
http://dx.doi.org/10.11613/BM.2016.041 Biochemia Medica 2016;26(3):376–94 
  385
Tešija Kuna A. et al. Autoimmune diagnostics in Croatia
2 . Initial sample dilution:
1 / 100 6 (0.86)




4 . Titration up to:
dilution with the last detectable fluorescence 2 (0.29)
1 / 320 2 (0.29)
1 / 10,000 1 (0.14)
1 / 40,960 1 (0.14)
we do not determine the titer 1 (0.14)
5 . Reporting of different patterns of fluorescence in the same sample:
Different fluorescence patterns but with only one titre 4 (0.57)
Different fluorescence patterns with corresponding titres 2 (0.29)
Different fluorescence patterns without titre 1 (0.14)
6 . Inclusion of interpretative comment on report:
Yes, in the case of fluorescence pattern indicating the presence of unusual antibodies (Golgi, lysosomes, 
peroxisomes, etc)
3 (0.43)*
Yes, in the case of cytoplasmic fluorescence patterns indicating the presence of SMA or AMA. 4 (0.57)*
No interpretative comment on report 1 (0.14)
7 . Examination of IIF slides:
Exclusively by one examiner 1 (0.14)
By two examiners with report issued in agreement 3 (0.43)
By one examiner in consultation with another if necessary 3 (0.43)
8 . Examination of IIF slides is done by:
Specialist in medical biochemistry and laboratory medicine 4 (0.57)
Master of medical biochemistry and laboratory medicine 2 (0.29)
Master of molecular biology 1 (0.14)
Assesment of ANA by methods other than IIF (N = 10) N 
(proportion)
1 . Specification of included antigens on laboratory report
Yes 5 (0.5)
No 5 (0.5)
Reflex testing for antibody specificities in ANA-screen positive samples (irrespective of method) (N = 14) ** N (proportion)
No 6 (0.43)
Yes, depending on the ANA titre 4 (0.29)
Yes, depending on the fluorescence pattern 2 (0.14)
If requested, irrespectively of ANA-screen test result 2 (0.14)
*One laboratory applies both offered options.**Answers obtained for 14 out of 17 laboratories that perform ANA testing.
ANA = antinuclear antibodies. IIF = Indirect immunofluorescence. Hep-2 cells = Human epithelial type 2 cells. FEIA = Fluorescence 
enzyme immunoassay. ELISA = Enzyme-linked immunosorbent assay. PCNA = Pleomorphic cell nuclear antigen. SMA = Smooth 
muscle antibodies. AMA = antimitochondrial antibodies.  
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also determines ENA specificities (9 / 17), some 
perform ANA, ENA-screen test and identification 
of ENA specificity (3 / 17) and one laboratory per-
forms ANA-screen test followed with ENA-screen 
without identification of specificities. Only one 
laboratory has the option for the second method 
for confirmation of ENA-specificity in the case of 
unclear results (Table 4). Four laboratories perform 
requested testing for ENA based on the result of 
ANA-screen test and only one laboratory applies 
the in-  house rule regarding the frequency of re-
peated testing for ENA-specificities (only in the 
case of the increase in ANA titre > 2 times or in the 
case of change in fluorescence pattern).
Anti-dsDNA testing is performed in 15 laboratories 
(Table 5). The vast majority of the laboratories per-
forming ANA testing also perform anti-dsDNA 
testing (15 / 17), either as the only specificity (3 / 
17) or together with anti-ENA (12 / 17). None of lab-
oratories declared more than one method for anti-
dsDNA determination, including the laboratory 
that uses CLIFT (Crithidia luciliae immunofluores-
cence test). 
Only three laboratories declared to perform ANA-
screen as the first line test were only anti-dsDNA 
and/or anti-ENA were requested.
Assessment of antiphospholipid antibodies 
Antiphospholipid (aPL) antibodies are determined 
in 12 / 33 laboratories. The most frequently deter-
mined antibodies are anticardiolipin antibodies 
(aCL-IgG and aCL-IgM) followed by anti-beta2-gly-
coprotein I (anti-B2GPI IgG and IgM) antibodies. 
Lupus anticoagulant (LA) are assessed in 6 / 12 lab-
oratories, including two specialized for transfusion 
medicine. Current practise in the assessment of 
antiphospholipid antibodies is presented in Table 
6. In the case that request refers only to aPL anti-
bodies without antibody specification, none of the 
laboratories apply any algorithm, but rather deter-
mine all available antiphospholipid antibodies (in-
cluding IgG and IgM isotypes) simultaneously. Out 
of eight laboratories that determine aCL antibod-
ies, five report results in GPL-U/mL and MPL-U/mL 
while three of them report in U/mL. Units for anti-
B2GPI antibodies are reported as U/mL or RU/mL. 





“Classic” ENA panel: SS-A/Ro60, SS-B/La, 
U1-RNP, Sm, Scl-70, Jo-1
4 (1.0)
Classic ENA panel + additional specificities: 
CENP, Ro52 (TRIM21), RNA-polymerase III, 





Semiquantitative (ratio) 1 (0.25)




MIA (Luminex) 3 (0.25)
LIA 1 (0.08)
FEIA + LIA 1 (0.08)
Specificities
SS-A/Ro60 12 (1.0)











ENA = extractible nuclear antibodies. FEIA = Fluorescence 
enzyme immunoassay. ELISA = Enzyme-linked 
immunosorbent assay. MIA = Multiplex bead immunoassay. 
LIA = Line immunoassay. SS-A/Ro60 = Anti-Sjögren’s-
syndrome-related antigen A. Ro52 (TRIM21) = Tripartite 
motif-containing protein 21. SS-B/La = Sjögren syndrome 
type B antigen. U1-RNP = U1 ribonucleoprotein. PM/Scl = 
Polymyositis/Scleroderma. PCNA = Pleomorphic cell nuclear 
antigen. Sm = Smith antigen. Scl-70 = topoisomerase I. Jo-1 
= histidyl tRNA synthetase. CENP = antibodies targeting 
centromere proteins. Mi-2 = myositis specific antibody.
Table 4. Current practice in assessment of ENA testing
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Algorithm applied for anti-dsDNA testing 
in regards to ANA-screen test 
(N = 12) **
N 
(proportion)
Only when requested, regardless of the 
ANA-screen result 6 (0.5)
As a reflex test on ANA-screen positive result 4 (0.33)
Only when requested and ANA-screen result 
is positive 1 (0.08)
Only when requested and ANA titer > 1 / 160 1 (0.08)
*Laboratory that uses CLIFT method. **Answers obtained 
for 12/15 laboratories. FEIA = Fluorescence enzyme 
immunoassay. ELISA = Enzyme-linked immunosorbent assay. 
MIA = Multiplex bead immunoassay. CLIFT = Crithidia luciliae 
immunofluorescence test.
Table 5. Current practice in assessment of anti-dsDNA testing
Regarding methods, ELISA is equally used for aCL 
and anti-B2GPI (4 laboratories), while FEIA is used 
in four laboratories for aCL and in three for anti- 
B2GPI. ELISA method is in use for aPS determina-
tion. 
Assessment of antibodies associated with 
systemic vasculitis and glomerulonephritis
Fourteen laboratories (14 / 33) determine any anti-
body associated with systemic vasculitis and glo-
merulonephritis: anti-neutrophil cytoplasmic anti-
bodies (ANCA), anti-proteinase 3 (anti-PR3), anti-
myeloperoxidase (anti-MPO), anti-glomerular 
Antibodies used in determination 
of aPL (N = 12)
N 
(proportion)
Only aCL (IgG and IgM) 2 (0.17)
Only LA 3 (0.25)
Only anti-B2GPI (IgG and IgM) 1 (0.08)
aCl (IgG and IgM) + anti-B2GPI (IgG and IgM) 2 (0.17)
aCl (IgG and IgM) + anti-B2GPI (IgG and IgM) 
+ LA 3 (0.25)
aCl (IgG and IgM) + anti-B2GPI (IgG and IgM) 
+ aPS 1 (0.08)
aPL = antiphospholipid antibodies. aCL = anticardiolipin 
antibodies. anti-B2GPI = anti-beta2 glycoprotein I antibodies. 
LA = lupus anticoagulant. aPS = antiphosphatidilserine 
antibodies.
Table 6. Current practice in assessment of antiphospholipid an-
tibodies (aPL)
basement membrane (anti-GBM) antibodies. All 14 
laboratories determine anti-PR3 and anti-MPO 
ANCA specificities by the following methods: FEIA 
(7 / 14), ELISA (4 /14), MIA (Luminex) (2 / 14) and im-
munoblot (IB) (1 / 14). Only four laboratories per-
form ANCA-screen test. Three of these four labora-
tories use method of indirect immunofluorescence 
(IIF) on ethanol-fixed granulocytes while one of 
them use ELISA test but without specification re-
garding target antigens. All four laboratories that 
perform ANCA-screen use the same algorithm: de-
termination of anti-PR3 and anti-MPO specificities 
only in ANCA-screen positive samples. Formalin-
fixed granulocytes are used simultaneously with 
ethanol-fixed granulocytes as substrates in two of 
three laboratories that perform IIF ANCA-screen 
while the third laboratory uses only ethanol-fixed 
granulocytes. ANCA cut off titre is 1 / 10 in two 
laboratories and 1 / 20 in one. All three laborato-
ries recognize following ANCA fluorescence pat-
terns: perinuclear (pANCA), cytoplasmic (cANCA), 
atypical perinuclear (a/pANCA) and one of them 
also recognizes atypical cytoplasmic (a/cANCA) 
fluorescence pattern. No ANCA-specificities other 
than PR3 and MPO are determined. Almost all (13 / 
14) laboratories that determine PR3/MPO specifici-
ties report results as quantitative: 8 report as U/
mL, 2 as RU/mL, and one of each as kIU/L, IU/mL 
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and AU/mL. Only 3 / 14 laboratories declared to 
perform anti-GBM determination with MIA (Lu-
minex) (Multiplexed bead immunoassay) method 
in 2 and IIF in 1 of them.
Assessment of antibodies associated with 
autoimmune liver diseases
Six laboratories declared to perform determina-
tion of antibodies associated with autoimmune 
liver diseases. Laboratories within tertiary health 
care facilities (4 / 6) determine all antibodies rele-
vant for autoimmune liver diseases: antimitochon-
drial antibodies (AMA), smooth muscle antibodies 
(SMA), anti-liver-kidney microsomal antibodies 
(anti-LKM), antibodies to liver cytosol (anti-LC-1) 
and antibodies to soluble liver antigen (anti-SLA). 
In these laboratories, AMA is determined by IIF 
method followed with confirmation of AMA-M2 
specificity in the case of positive result. AMA titre 
is reported in 2 / 4 laboratories while in other two 
results are reported only as positive or negative. 
Titre of SMA antibodies is reported in 2 / 4 labora-
tories, one reports qualitative result and one did 
not specify the way of reporting the results. Anti-
LKM antibodies are determined by IIF method fol-
lowed with confirmation of LKM-1 in the case of 
positive result in 3 / 4 laboratories. Only one labo-
ratory declared to report the titre of anti-LKM anti-
bodies. The other two of six laboratories that de-
clared to determine antibodies associated with au-
toimmune liver diseases, determine only anti-LKM 
and AMA in one of them and anti-LKM only in oth-
er. In both cases, solid assays are used (FEIA for 
AMA and ELISA for anti-LKM). None of the labora-
tories determines antibodies targeting asialogly-
coprotein receptor (ASGPR).
Assessment of antibodies associated 
with autoimmune diseases affecting the 
gastrointestinal system
In total, 11 of 33 laboratories declared to deter-
mine any of antibodies associated with gastroin-
testinal autoimmune diseases. All of them deter-
mine antibodies associated with celiac disease (Ta-
ble 7) Regarding antibodies associated with in-
flammatory bowel diseases (ulcerative colitis and 
Antibodies used in immunodiagnostic of 
celiac disease (N = 11)
N 
(proportion)
Methods used for anti-tTG determination (N = 11)
ELISA 3 (0.27)
FEIA 5 (0.45)
MIA (Luminex) 2 (0.18)
Immunocromatography 1 (0.09)
Methods used for anti-DPG determination (N = 5)
FEIA 3 (0.6)
MIA (Luminex) 2 (0.4)
Methods used for EMA determination (N = 4)
IIF 3 (0.75)
ELISA 1 (0.25)
Methods used for AGA determination (N = 3)
MIA (Luminex) 2 (0.67)
FEIA 1 (0.33)




Algorithms in diagnosis of celiac disease (N = 11)
Measurement of total IgA precedes 
determination of IgA class antibodies 
5 (0.45)
IgG class of antibodies associated with celiac 
disease determined only in the cases of IgA 
deficiency and in children ≤ 2 years old.
3 (0.27)
IgG class of antibodies associated with celiac 
disease always determined together with IgA 
class antibodies.
2 (0.18)
anti-tTG = antibodies against tissue transglutaminase. ELISA 
= Enzyme-linked immunosorbent assay. FEIA = Fluorescence 
enzyme immunoassay. MIA = Multiplex bead immunoassay. 
anti-DGP = antibodies targeting deamidated gliadin 
peptides. EMA = anti-endomysium antibodies. IIF = Indirect 
immunofluorescence. AGA = antibodies against native 
gliadin. 
Table 7. Current practice in immunodiagnostic of celiac disease
Crohn’s disease), determination of ANCA antibod-
ies is already stated within the results regarding 
antibodies associated with systemic vasculitis 
while anti-saccharomyces cerevisiae (ASCA) anti-
bodies are determined in only one, private labora-
tory using ELISA method. No laboratories declared 
to determine any other antibody associated with 
inflammatory bowel diseases. Antibodies against 
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parietal cells (APCA) are determined in only two 
laboratories, both within tertiary health care facili-
ties and both use IIF method.
Assessment of antibodies associated with 
autoimmune diseases affecting nervous 
system
These antibodies are most rarely determined, in 
only two laboratories within tertiary healthcare fa-
cilities. In both laboratories, antibodies associated 
with paraneoplastic neurological syndrome are 
determined: anti-Hu, anti-Yo and anti-Ri antibod-
ies. One laboratory uses only IIF method while the 
other one uses IIF followed with immunoblot (IB) 
method for confirmation.
External quality assessment
Out of 33 laboratories that perform autoimmune 
diagnostic tests, only 13 participate in external 
quality assessment (EQA) with the full scope of the 
analysis (Table 1). Three laboratories have not pro-
vided answer to EQA question in the Survey.  
One of five laboratories that partially participated 
in EQA did not specify the tests that are included, 
while the participation of other four was heteroge-
neous regarding the tests. Six out of twelve labo-
ratories that do not participate in EQA are labora-
tories that perform only RF and/or anti-CCP, or LA 
exclusively in 2 / 12. Also, 2 / 12 laboratories that 
do not participate with any of the analysis they 
perform stated the intention to fully participate in 
EQA starting with the beginning of the following 
year.
Discussion
Results of conducted survey confirmed not only 
high heterogeneity in the performance of autoan-
tibody testing among laboratories in Croatia, but 
also obsolete in some cases. This includes issues 
with result reporting, determination of serological 
markers that are not recommended, methods of 
determination of certain markers that do not com-
ply with existing international recommendations 
or the application of very heterogeneous algo-
rithms among laboratories. 
Most of the laboratories perform tests for immu-
nodiagnostic of systemic autoimmune rheumatic 
diseases (SARD), predominantly serological mark-
ers of rheumatoid arthritis, RF and anti-CCP. This 
result was expected taking into account a few 
facts: a) RA is the most common systemic autoim-
mune disease, b) both markers are part of RA clas-
sification criteria (5), c) both markers are deter-
mined using methods set to automatic analysers, 
which already exist in most laboratories and do 
not require additional equipment. These automat-
ed methods for determining RF and anti-CCP are 
responsible for the fact that many laboratories (12 
of 14) report the analysis results in this field of lab-
oratory diagnostics within 24 hours. After RF and 
anti-CCP, ANA is the most commonly performed 
test (17 / 80 laboratories in total). In comparison 
with the study conducted by the EASI group (13) 
regarding the implementation of the ANA test in 
12 European countries, the number of laboratories 
performing ANA regarding the total population in 
Croatia is comparable with France, the Nether-
lands and Switzerland. Half of the laboratories in 
Croatia that determine ANA belong to University 
hospital or University hospital centres while in 
most European countries to general hospitals or 
private institutions (with the exception of Norway 
and Sweden, where the ratio is equal). In order to 
meet the increasing demand for ANA determina-
tion, reducing costs and compensating the lack of 
experienced personnel for interpretation of ANA 
fluorescence, the preference to the alternative sol-
id phase automated assays with very diverse sensi-
tivity and specificity is often given over IIF screen-
ing method. The main reason for this diversity lies 
in the fact that commercial kits from different 
manufactures use different methods, mixture of 
purified extracts or recombinant antigens, and 
number of antigens included in mixture (14,15). Us-
ing IIF method on Hep-2, larger number of nuclear, 
nucleolar and cytoplasmic antigens could be de-
tected when compared to solid phase assays 
where detection is possible only for antigens in-
cluded in the mixture. Sensitivity and specificity of 
ANA-screen using enzyme-based immunoassay 
(EIA) were examined for nine manufactures kits in 
study of Tan et al. (16). Results showed good sensi-
tivity and specificity with the need for improve-
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ment in detection of anti-dsDNA and anti-Sm in 
some kits. Sensitivity and specificity using differ-
ent methods and comparing them to IIF, show dif-
ferent results depending on used method (14-17). 
Due to significant number of false negative results 
when using these methods, IIF method on Hep-2 
cells is still considered a reference method for ANA 
screening (3,14). However, one should keep in 
mind that choice of ANA detection method is ac-
tually disease-dependent. For example, ANA is the 
serologic marker of autoimmune hepatitis but 
without clearly associated antigen specificity and 
therefore IIF method is the only one applicable in 
this case (10). On the other hand, myositis is associ-
ated with Jo-1 antibodies which can be accurately 
detected only with solid phase assays (2,14). Since 
laboratory staff is mostly unaware of suspected di-
agnosis, some authors support the opinion that 
multiple screening tests should be used in order 
to improve the diagnostic of autoimmune diseases 
but with appropriate comments included for inter-
pretation of discrepant results (18,19). With the 
share of only 7 / 17 laboratories that perform ANA- 
screening with IIF method, Croatia is next-to-last 
in comparison to European countries that partici-
pated in EASI group Survey (13). In fact, in most Eu-
ropean countries IIF method is applied in > 90% of 
laboratories with the exception of the Nether-
lands, Portugal, Norway and Ukraine (with 65%, 
64%, 50% and 40% share respectively). The man-
ner of conducting ANA-screen with IIF in Croatia is 
rather homogenous, in the sense that all laborato-
ries recognize and report at least 4 regular fluores-
cence patterns and all except one provide titre 
and interpretative comments. Given that low ANA 
titres are common in the older population as well 
as in some other diseases in addition to SARD, 
qualitative ANA result does not give sufficient clin-
ical information (14). Beside four regular nuclear 
patterns, cytoplasmic fluorescence patterns are 
very common and usually address the presence of 
other antibodies such as antimitochondrial (AMA) 
or smooth muscle antibodies (SMA) associated 
with autoimmune liver diseases (3). Also, cytoplas-
mic fluorescence can reflect the presence of other 
important SARD-associated antibodies such as 
those targeting ribosomal-P proteins or Ro52 (14). 
Therefore, negligence of cytoplasmic fluorescence 
can have clinical consequences such as delay in 
proper diagnosis. Although initial (screening) dilu-
tions most commonly present throughout litera-
ture are 1 / 80 or 1 / 160, it is generally recom-
mended that the laboratory appoints the initial di-
lution that corresponds to 95th percentile of local 
healthy population (with respective shares regard-
ing age and gender) (1,3). However, very often the 
IIF reagent kit manufacturer proposed initial dilu-
tion is applied. Given the fact that Croatia is a small 
market, the same reagent manufacturer probably 
recommends the initial dilution 1 / 100 used by 6 / 
7 laboratories. Distinct heterogeneity still exists in 
the titration level of positive samples with only 
two laboratories following the recommendation 
of reporting the last dilution which still shows re-
activity (3). In addition, heterogeneity exists in re-
porting different patterns with different fluores-
cence intensity observed in one sample. Positive 
finding is that all except one laboratory perform-
ing ANA-screen by IIF method consider the oppor-
tunity of more than one observer in the case of a 
doubtful result. Surprisingly poor result of the sur-
vey was that half (5 / 10) of laboratories that use 
solid phase assays for ANA-screening do not speci-
fy antigens included in the assay (3). If the clinician 
is not aware that applied method covers only the 
limited number of antigens, one can consider it 
equivalent to IIF screening assay. Commercial solid 
phase assays usually include clinically most rele-
vant antigens such as SS-A/Ro60, SS-B/La, Sm, 
U1RNP, dsDNA, Scl-70, Jo-1 and CENP. However, 
some antigens clinically relevant for systemic scle-
rosis, such as RNA-polymerase III or some nucleolar 
antigens such as PM-ScL or fibrillarin are rarely in-
cluded in these assays (3,8). The same refers to his-
tones as the target antigens for ANA associated 
with drug induced lupus, which are rarely included 
in ANA-screen solid phase assays so that the false 
negative ANA result can lead to misdiagnose (3). 
Most laboratories that perform ANA testing also 
perform anti-ENA testing. However, the approach 
to ANA and anti-ENA testing is quite heterogene-
ous and even pointless in some cases (ANA solid 
assay followed with ENA-screen assay). According 
to current practice, anti-ENA determination in Cro-
atia is somewhat lower (77%) in comparison to 
other European countries (except Ukraine) where 
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more than 83% of laboratories that perform ANA 
testing also perform anti-ENA testing (13,20). At 
least, the most relevant ENA antigens (SS-A/Ro60, 
SS-B/La, Sm, U1RNP, Scl-70, and Jo-1) are included 
in all ENA-screen assays. Regarding the identifica-
tion of ENA specificities, all laboratories determine 
antibodies to SS-A/Ro60, SS-B/La, RNP and Scl-70 
while one laboratory does not test for Sm and Jo-1 
antibodies. In general, the extent of ENA-specifici-
ties determination is lower in Croatia in compari-
son to other European countries but the covered 
specificities are comparable (13). Distinction be-
tween anti-SS-A/Ro60 and anti-Ro52 (TRIM21) anti-
bodies was found in 42% (5 / 12) of Croatian labora-
tories which determines ENA specificities, in com-
parison to only 20–25% of laboratories in other Eu-
ropean countries. On the one hand it could be at-
tributed to the higher awareness of different clini-
cal relevance regarding monoreactivity to Ro52 
antigen (in myositis and systemic sclerosis) or SS-A/
Ro60 antigen (in subacute lupus) (21). On the other 
hand, some laboratories do not use single tests for 
specificity confirmation but in order to reduce the 
cost and time for analysis, rather use the panel of 
different specificities. Therefore, it could be that 
number of individual specificities is simply dictated 
by the available commercial products. Another in-
teresting finding is that 3 / 12 laboratories deter-
mine RNP70 specificity either with or without 
U1RNP specificity (encompasses proteins A, C, and 
70kD). Although the anti-U1RNP immune response 
targets all three protein components (70kDa, A, C), 
individual reactivity to 70kDa protein may be more 
specific for mixed connective tissue disease (MCTD) 
as it is less frequent in SLE than those to proteins A 
or C (22). However, the best sensitivity and specific-
ity for MCTD seems to be achieved with identifica-
tion of both U1RNP and RNP70 (23).
In spite of recommendation to use additional 
method in the case of result discrepancy between 
anti-ENA and ANA or with clinical suspicion, only 
one laboratory has the opportunity of using alter-
native method for anti-ENA (3). 
Regarding anti-dsDNA testing, none of laborato-
ries use Farr assay (radioimmunoassay, RIA) that is 
based on precipitation of antibody-antigen com-
plexes using ammonium sulphate and the quanti-
fication of antibody in the precipitate using a ra-
dio-labelled dsDNA antigen. Farr assay is consid-
ered to be the gold standard but it is also minimal-
ly present in laboratories throughout Europe, most 
probably due to use of radioisotopes and labori-
ousness of the method (24). CLIFT as a second 
choice according to specificity is variable present 
(26–94%) in European laboratories while in Croatia 
only one laboratory uses this method (13). Howev-
er, no quantitative method for detection of anti-
dsDNA is in use in this laboratory so that the pa-
tient cannot be followed. Although all except one 
laboratory report quantitative result for anti-dsD-
NA there is considerable heterogeneity in report-
ing units. Since commercial tests are calibrated 
against the 1st International Standard for anti-dsD-
NA coded Wo/80, results should be given in Inter-
national Units (IU/mL).
The majority of laboratories do not apply algo-
rithms for testing anti-ENA or anti-dsDNA based 
on ANA-screen result but strictly adhere to the re-
quested tests. The most probable explanation is 
that the Croatian health reimbursement policy 
does not consider reflex testing. 
Most laboratories do not apply any rules regarding 
minimal retesting interval. This issue primarily re-
fers to frequent requests for ANA retesting or for 
retesting of previously confirmed ENA-specificity. 
Repeat testing for ANA titre does not have con-
firmed value in assessing the disease activity and 
retesting for ENA-specificity can be justified only 
in the case of the appearance of new symptoms 
(2). Our data are comparable to the results of Cana-
dian study that pointed out unnecessary repeat 
testing and simultaneous ordering of multiple 
tests (ANA, ENA, dsDNA) (25).
General impression of the Survey results regarding 
ANA testing is that the consultative role of labora-
tory experts in immunodiagnostic workout is 
poorly involved or limited only to an interpretative 
comment, eventually. 
Testing for antiphospholipid antibodies is per-
formed in 15% (12 / 80) of laboratories within ter-
tiary and secondary health care facilities and pri-
vate health care institutions. The minority of labo-
ratories covers determination of all antibodies in-
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cluded in APS-classification criteria (9). It can par-
tially be explained with the policy in some hospi-
tals to perform determination of LA within the 
framework of transfusion medicine instead of 
medical biochemistry laboratory. There is consid-
erable heterogeneity regarding reporting of the 
units for anticardiolipin antibodies with almost 
half of laboratories not following the International 
guidelines on anticardiolipin testing (26).
Assessment of antibodies associated with system-
ic vasculitis and glomerulonephritis is performed 
in 17% (14 / 80) of included laboratories. The cur-
rent approach of ANCA determination in Croatian 
laboratories implies quantitative (in all but one 
laboratory) determination of PR3 and MPO specifi-
cities only, while ANCA-screen is performed in mi-
nority of laboratories. All three laboratories that 
use IIF method for ANCA-screen apply the same 
algorithm with obligatory testing for PR3/MPO 
specificity in ANCA IIF positive samples and also 
recognize and report the fluorescence patterns in 
line with International consensus statement on 
testing and reporting of ANCA (27,28). Use of quali-
tative test for PR3/MPO specificities is limited to di-
agnosis purpose in emergency cases and, unlike 
quantitative test, has no value in monitoring the 
inflammatory activity of vasculitis.
Assessment of autoantibodies associated with au-
toimmune liver diseases is poorly present in Croa-
tian laboratories and is mostly limited to laborato-
ries within University hospitals. There is considera-
ble heterogeneity in the approach to determina-
tion of SMA and LKM antibodies by IIF method 
concerning reporting titre. Namely, half of labora-
tories do not report titre for SMA while for anti-
LKM all except one do not report titre. This policy 
is not in line with the guidelines of International 
Autoimmune Hepatitis Group which includes a 
Scoring System for diagnosis of autoimmune hep-
atitis based on the titre of relevant autoantibodies 
(ANA, SMA, LKM) (29-31). For the same reason, use 
of solely solid assays for detection of anti-LKM an-
tibodies is not suitable, but should rather be used 
for confirmation of LKM-1 reactivity in samples 
with LKM-typical fluorescence pattern. Although, 
determination of AMA titre has no approved clini-
cal value, half of laboratories report titre.
Among antibodies associated with gastrointesti-
nal autoimmune diseases, determination of those 
associated with celiac disease are most frequently 
performed, with anti-tTG IgA, as the first line test, 
being the most prominent. Antibodies to native 
gliadin (AGA) are still sporadically determined al-
though all the relevant guidelines discourage use 
of these antibodies in diagnosis of celiac disease 
(12,32). Algorithms applied in serologic diagnosis 
of celiac disease are heterogeneous and almost 
half laboratories do not follow the guidelines on 
the determination of IgG class of antibodies or to-
tal IgA (12). 
Regarding antibodies associated with inflammato-
ry bowel diseases (IBD) it is important to point out 
that ANCA associated with these diseases targets a 
wide range of possible antigens but not PR3 and 
MPO (33). IBD associated ANCA are commonly de-
tected only by IIF method without confirmation of 
specificity. Using the term “ANCA” for specific anti-
PR3 or anti-MPO tests can be misleading for clini-
cian seeking for ANCA in IBD. ANCA specificities 
relevant for IBD are not detected in the Croatian 
public medical laboratories and also rarely in pri-
vate laboratories.
Determination of antibodies associated with auto-
immune diseases affecting nervous system is most 
rarely performed and are limited only to antibod-
ies in paraneoplastic syndrome.
Considering participation in EQA, the results clear-
ly show that not enough laboratories participate 
in EQA schemes. This could partially be explained 
by the fact that the national program for external 
control provided by the Croatian Centre for Quali-
ty Assessment in Laboratory Medicine (CROQALM) 
does not cover tests from this scope. Participation 
in EQA is especially important for autoantibody 
testing since these methods are not standardized 
and use exclusively manufacturer - dependent 
quality control samples which makes the objective 
evidence of laboratory competence limited (34). 
Participation in EQA offers the opportunity for lab-
oratory to compare own results with those ob-
tained with other participants that use same or 
different methodologies (35). The efforts to moti-
vate or obligate laboratories to participate in EQA 
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schemes should be made with a help of national 
professional associations. This process could also 
be facilitated with the decision to participate in 
the accreditation process according to HRN EN ISO 
15189 in the field of humoral laboratory diagnostic 
of autoimmune diseases. 
Considering all challenges that our study indicates, 
the Italian multicentre study showed how devel-
opment and implementation of diagnostics algo-
rithms and recommendations contribute to diag-
nostic specificity of autoimmune rheumatic dis-
eases (36). Limitation of this study could be attrib-
uted to all the disadvantages of using online sur-
vey to collect data about current practice in labo-
ratory diagnostics of autoimmune diseases in Cro-
atia. The main disadvantage is that the answers to 
the questions depend on respondents’ honesty 
regarding the real situation in laboratory practice 
of autoimmune diseases diagnostics. The other 
limitation of the study is limited number of organ-
specific autoimmune diseases included. 
In conclusion, the survey results indicate the het-
erogeneity in the manner of conducting the hu-
moral immunodiagnostic of autoimmune diseases 
throughout laboratories in Croatia. This heteroge-
neity refers not only to the use of different meth-
ods, analytical platforms or algorithms but also to 
the use of the same method and to the policy of 
results reporting. Such heterogeneity on the level 
of laboratory diagnostics most certainly has an im-
pact on the clinical level. Therefore, presented 
data stressed out the necessity for recommenda-
tions on national level with the aim to harmonize 
this specific branch of laboratory diagnostic. In is-
suing recommendations, currently used method-
ologies as well as the national health reimburse-
ment policy, which for example, does not consider 
reflex testing should be taken into the considera-
tion.
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